Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 7/20 | 0.47 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.47 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869978 | 0.79 | FAAH (0.53) | AVPR1AAVPR1BAVPR2TP53MEN1 | |
| SCHEMBL4863182 | 0.77 | AVPR1A (0.53) | AVPR1AAVPR1BAVPR2TP53LMNA | |
| SCHEMBL6991954 | 0.71 | AVPR1A (0.65) | AVPR1AAVPR1BAVPR2TP53MEN1 | |
| SCHEMBL10996089 | 0.70 | MEN1 (0.54) | MEN1KMT2A | |
| SCHEMBL19454437 | 0.69 | NPC1 (0.57) | AVPR1AAVPR1BAVPR2MEN1KMT2A | |
| SCHEMBL8416762 | 0.66 | GAA (0.53) | LMNAMEN1KMT2APOLB | |
| SCHEMBL4868466 | 0.66 | MAPT (0.69) | TP53LMNAMEN1HTTKMT2A | |
| SCHEMBL4868982 | 0.66 | MEN1 (0.60) | TP53LMNAMEN1HTTKMT2A | |
| SCHEMBL4870679 | 0.66 | TP53 (0.67) | AVPR1AAVPR2TP53LMNAMEN1 | |
| SCHEMBL6988048 | 0.66 | NAAA (0.55) | AVPR1AAVPR1BAVPR2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | AVPR1A 276/4885AVPR1B 189/4885AVPR2 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.